Drugmaker Settles Free Speech Dispute as FDA Agrees on LabelBy
Pacira reaches deal with FDA over post-surgical drug Exparel
Label to say treatment isn't limited to any specific surgery
U.S. regulators have backed off an attempt to limit Pacira Pharmaceuticals Inc.’s promotion of its pain drug, striking an agreement that’s likely to fan the flames of debate over free speech and drug marketing. The company’s shares climbed as much as 20 percent.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.